Feline GLP-1/GIP Dual Agonist HDM7006 Shows Weekly Dosing Profile in Cats
A pharmacokinetic study published in Frontiers in Veterinary Science reports that HDM7006, an experimental GLP-1/GIP dual agonist developed by Huadong Medicine, has a half-life of roughly 40–52 hours in healthy laboratory cats and supports once-weekly subcutaneous dosing. The findings, which come from a small number of young, purebred research animals, are early-stage and do not establish clinical efficacy or safety in client-owned pets.
The study matters for the peptide therapy and research peptide industry because it extends the GLP-1/GIP dual agonist class beyond human metabolic medicine into veterinary applications. It also highlights how pharmacokinetic data, receptor potency assays and immunogenicity testing are becoming standard parts of peptide drug development, even in animal health. For clinics, telehealth operators and research suppliers tracking the GLP-1 supply chain, the cat study is a reminder that demand for peptide APIs and finished injectable formats may eventually broaden beyond human patients.
What happened: a pharmacokinetic study in healthy cats
HDM7006 is a 46-amino-acid peptide that activates both the GLP-1 receptor and the GIP receptor, according to the study authors. It carries the human-medicine code name HDM1005. In laboratory cell assays, the compound showed higher potency at the feline GLP-1 receptor than tirzepatide, with EC50 values of 7.95 picomolar in cats versus 379.10 picomolar for tirzepatide; in human receptors, the values were 2.67 picomolar for HDM7006 and 12.04 picomolar for tirzepatide. At the GIP receptor, HDM7006’s potency was comparable to tirzepatide’s.
After a single 1.0 mg/kg intravenous dose in cats, mean initial concentration was 26,632 ng/mL, elimination half-life was 43.7 hours, clearance was 1.62 mL/h/kg and volume of distribution was 99.2 mL/kg. Subcutaneous dosing produced median time to peak concentration of 18.0–24.0 hours across four dose levels, with half-lives of 39.8–47.1 hours. Absolute bioavailability ranged from 42.23% at 0.1 mg/kg to 78.38% at 1.0 mg/kg. A power-model analysis found 90% confidence intervals of the slopes for Cmax and AUC within the pre-defined 0.77–1.23 interval, indicating linear, dose-proportional pharmacokinetics over 0.1–2.0 mg/kg.
After five weekly 0.5 mg/kg subcutaneous doses, steady state was reached after about three doses, with trough concentrations before doses 3–5 of 547–608 ng/mL and an accumulation index of 1.12. Steady-state peak averaged 2,199 ng/mL versus 2,116 ng/mL after the first dose, and terminal half-life was 52.1 hours. Sex had no detectable effect on exposure (all p-values >0.05; female-to-male ratios 0.5–2.0), so the authors pooled sexes for primary analyses.
Key numbers from the feline study
| Parameter | Result |
|---|---|
| Half-life (IV, 1.0 mg/kg) | 43.7 hours |
| Half-life (SC, across doses) | 39.8–47.1 hours |
| Clearance (IV) | 1.62 mL/h/kg |
| Volume of distribution (IV) | 99.2 mL/kg |
| Absolute bioavailability (SC) | 42.23%–78.38% |
| Median Tmax (SC) | 18.0–24.0 hours |
| Accumulation index (five weekly doses) | 1.12 |
| Anti-drug antibody rate (single dose) | 1.33% (2 of 152 samples) |
| Anti-drug antibody rate (repeated dose) | 0% (0 of 35 samples) |
Immunogenicity was low: anti-drug antibodies were detected in only 2 of 152 single-dose samples (1.33%), both from one male cat in the highest dose group at 336 hours post-dose with low titers of 20. All 35 repeated-dose samples were negative. The authors note that immunogenicity is a key regulatory concern for peptide therapeutics, as highlighted in a 2023 US Food and Drug Administration guideline.
Why it matters for peptide therapy and research peptides
The study is a preclinical pharmacokinetic investigation, not a clinical trial. It does not show that HDM7006 is safe or effective for weight management in cats, and no weight-loss drug has yet been approved for pet cats. The World Small Animal Veterinary Association classifies obesity as a disease, linking it to diabetes, cardiovascular conditions and arthritis, and surveys cited by the authors suggest a substantial and apparently growing prevalence of overweight pets in the United States, China and elsewhere. That context explains commercial interest, but it does not establish that HDM7006 will reach the market.
For the peptide therapy industry, the cat study illustrates the widening scope of GLP-1/GIP dual agonists. These molecules are already central to human metabolic medicine, and their extension into veterinary medicine could eventually affect demand for peptide APIs, fill-finish capacity for vials and cartridges, and cold-chain logistics. However, the available evidence does not yet establish that a veterinary market will materialize at scale. Clinics and telehealth operators that follow GLP-1 trends should treat this as an early signal rather than a near-term commercial opportunity.
For research peptide suppliers and laboratories, the study reinforces the importance of analytical characterization. Receptor potency assays, pharmacokinetic sampling and anti-drug antibody testing are specialized capabilities. Research peptides are for research use only and must not be described as approved treatments. Any human use of GLP-1 receptor agonists requires prescription and medical supervision. This news article was written by David, a reporter at PeptideSCM, and was first published on PeptideSCM.com.
Research and market context
HDM7006 is being developed by Huadong Medicine, a Chinese pharmaceutical company. The same research group previously reported that weekly subcutaneous HDM7006 in obese cats produced dose-dependent weight reductions of 8.42%, 13.71% and 19.45% in low-, medium- and high-dose titration groups versus vehicle controls. That earlier pharmacodynamic work is preclinical and involved small groups; it does not prove clinical benefit in client-owned animals.
The pharmacokinetic profile reported here—roughly 44-hour half-life, dose-proportional exposure and minimal antibody formation—is consistent with once-weekly dosing, according to the authors. They conclude that the data warrant further investigation in diabetic and overweight cats. The study’s limitations are significant: the findings come from a small number of healthy, young, purebred laboratory cats, so how the drug performs in older, obese, client-owned animals with concurrent disease remains to be demonstrated in the clinical trials now planned.
Two cats were withdrawn for stress reactions: one female in the 1.0 mg/kg single-dose group on day eight, and one female in the multiple-dose group after five days. The main clinical observation was anorexia, which the authors attribute to the drug’s intended appetite-suppressing pharmacology rather than to unexpected toxicity. No other adverse reactions were reported. The authors caution that cats are unusually sensitive to handling and sampling procedures, which may have compounded the stress responses in the two excluded animals.
PeptideDDP is a valuable source of frontline industry intelligence. Visit PeptideDDP.com for the latest first-hand information and industry updates.
What comes next
The authors propose clinical trials in diabetic and overweight cats. Key questions include whether the pharmacokinetic profile translates into reliable once-weekly exposure in older, diseased animals, and whether the low immunogenicity seen in healthy young cats holds in a broader population. Regulatory acceptance is another unknown: no weight-loss drug has yet been approved for pet cats, and the pathway for veterinary GLP-1/GIP dual agonists is not established.
For industry observers, the study is a data point in the broader trend of peptide drug development moving across species. It does not change the human GLP-1 market, but it adds to the evidence base that dual agonists can be engineered for once-weekly dosing and low immunogenicity. Companies involved in peptide API manufacturing, fill-finish and cold-chain logistics may watch veterinary programs as a long-term demand signal, while keeping in mind that clinical and regulatory hurdles remain high.
Readers seeking reliable information on peptide safety should consult official regulatory databases, approved prescribing information, clinical trial registries and peer-reviewed literature. For research peptides, quality documentation such as batch-specific certificates of analysis, impurity profiles and stability data are essential; however, a certificate of analysis does not establish clinical safety or suitability for human administration. Additional industry resources and supply-chain intelligence are available through peptidescm.